Navigation Links
Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract
Date:3/28/2008

Ferring, Inc. Delivers the Purchase Order Which will Commence the Marketing

of Resurgex Select into the Canadian Oncology Market

BASKING RIDGE, N.J., March 28 /PRNewswire-FirstCall/ -- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (MBTG) announced today that it has received an $88,000 purchase order and letter of credit associated with the recently announced distribution agreement with Ferring, Inc. of Canada. Ferring, Inc. will commence the marketing and distribution of the Resurgex Select(R) product line into the Canadian Oncology marketplace upon the receipt of goods from Millennium this spring.

Ferring Canada is one of 40 Ferring S.A. operations located around the world which will launch Ferring's new Prostate Cancer Drug in 2010. This significant initiative offers a platform for Millennium to launch Resurgex throughout the Ferring global network.

The receipt of the guaranteed letter of credit validates Millennium's expansion into the international clinical oncology marketplace. International marketing and distribution partners in the oncology markets of Greece and now Canada have voluntarily embraced the opportunity to sell the Resurgex Select(R) product line within their respective countries.

Frank Guarino Chief Financial Officer of Millennium stated, "The culmination of this distribution agreement with Ferring, Inc. and the $88,000 letter of credit represents substantial progress for the Resurgex Select(R) product line. This event clearly verifies the revenue growth, future potential and clinical acceptance of the Resurgex Select(R) product line in the international nutritional supplement market."

Ferring is a Swiss-based, research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, fertility and urology.

Ab
'/>"/>

SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Smart Medical Technology, Inc. Awarded Novation Contract for Ground-breaking Liftaem(TM) System that Aids Lifting and Transferring Patients
4. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
5. Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing
6. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
7. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
8. Pharmos Corporation Completes Initial Closing of Private Placement
9. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
10. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
11. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... The Alliance for Clinical ... non-profit collaborative building a global system to enhance ... announced Phase 3 of its Site Accreditation and ... H. Kalali, Vice-President, Global Head, Neuroscience Center of ... and Quality Integration (CQI) Consulting will lead the ...
(Date:9/16/2014)... strap that can harvest energy from jaw movements has ... , It is hoped that the device can generate ... number of small-scale implantable or wearable electronic devices, such ... communication devices. , The first results of the device,s ... Publishing,s journal Smart Materials and Structures . , ...
Breaking Biology Technology:Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2
... ... in Arizona ,with State of the Art 3D Dedicated Neurology Suite, , ... (PRWEB) June 28, 2010 -- ... in the state of Arizona to adopt TrueVision® 3D Surgical Visualization, where multiple 3D ...
... ORLANDO, Fla. , June 26 Orexigen® Therapeutics, ... open-label study demonstrating that treatment with Contrave® resulted in significant improvements ... control of eating in overweight and obese patients with major depression. ... The ...
... 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... an integrated database of clinical studies that showed no ... (pramlintide acetate) injection use compared to a pooled comparator ... findings were presented at the 70th Annual Scientific Sessions ...
Cached Biology Technology:Cardon Children's Medical Center Adopts TrueVision 3D Surgical Visualization Platform for Department of Pediatric Neurosurgery 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 3Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 4Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 2Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 3Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 6Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 7
(Date:9/16/2014)... consumers to make ethical choices such as buying clothing ... on fair-trade coffee, and bringing their own bags when ... the Journal of Consumer Research , ethical consumption ... their emotions about unethical practices into action. , "Advocates ... environmental and human costs of the products they choose, ...
(Date:9/16/2014)...  Valencell, Inc., a leader in performance biometric data ... "Showcase Companies" representing North Carolina,s ... Venture Conference on September 16-17 th at the ... Raleigh, North Carolina . Valencell,s President Dr. ... the "Digital Health Spotlight Sector" on how the Company,s ...
(Date:9/16/2014)... of wild foods, autumn harks a season of bounty. ... luring intrepid collectors to woodlands in search of elusive ... in the allure of the treasure hunt, and their ... existence. But are the mushrooms which you are eating ... diverse yet vastly underdocumented although some estimates range ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3
... Over 50 leading experts will meet today in Brussels, ... cocoa flavanol research and the key findings of FLAVIOLA ... flavanols, their health benefits and potential applications. Members of ... of international researchers to review the outcomes of FLAVIOLA,s ...
... What cancerous conditions lead to what kinds of bacterial infections? ... benefit from pre-treatment with certain kinds of antibiotics. A University ... of the International Journal of Infectious Diseases shows ... are especially prevalent in patients with lung and GI ...
... that are socially isolated during a critical period of ... alcohol, found researchers at The University of Texas at ... the socially isolated rats. These effects, which are ... persist even after the rats are reintroduced into the ...
Cached Biology News:Recent breakthroughs in cocoa flavanol research discussed by European research consortium and expert panel 2Planning for bacteria in cancer patients may help hospitals fight infections 2Socially isolated rats are more vulnerable to addiction, report researchers 2Socially isolated rats are more vulnerable to addiction, report researchers 3
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
Request Info...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Biology Products: